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Background: This study aims to derive and validate a risk-
scoring algorithm to accurately identify asymptomatic patients at
increased risk for chlamydia and gonorrhea (CT/GC) infection.
Methods & Materials: This study is a population-based, cross-
sectional analysis of electronic records of visits collected at
two publicly funded sexual health clinics in Vancouver, British
Columbia between 2000 and 2012. We conducted multivariate
logistic regression of ﬁrst 7 years (2000-2006) of clinic visits data
(derivation population). We identiﬁed signiﬁcant predictors of
CT/GC infection from the ﬁnal regressionmodel and thenweighted
and summed their regression coefﬁcients to calculate a risk score
for each individual that is a direct reﬂection of the probability
of infection. The model’s discriminative and calibration perfor-
mance was evaluated using the area under the receiver operating
characteristic curve (AUC) and the Hosmer-Lemeshow (H-L) statis-
tic, respective. We examined the sensitivity (i.e., proportion of all
cases identiﬁed) and fraction of patients that would need to be
screened at different cutoffs of the risk score. Temporal validation
was assessed using clinic visits from 2007-2012.
Results: The prevalence of infection was 1.8% (n=13,791) and
2.1% (n=18,050) in the derivation and validation datasets, respec-
tively. The ﬁnal logistic regression model included male gender,
younger age, non-white ethnicity, multiple sexual partners and
previous CT/GC diagnosis. The model showed reasonable perfor-
mance in the derivation (AUC, 0.74; H-L p=0.99) and validation
(AUC, 0.64; H-L p=0.78) datasets. Possible risk scores ranged from
-3 and 25.We identiﬁed a risk score cutoff point of≥4 that detected
cases with a sensitivity of 89% and 80% by screening 64% and 63%
of the derivation and validation populations, respectively.
Conclusion: This is the ﬁrst study in sexual health contexts that
derived and temporally validated a well-performing risk-scoring
algorithm for screening asymptomatic CT/GC infection, an issue
particularly salient in this ﬁeld because of the shift to more sen-
sitive diagnostic tests over this time period. These ﬁndings support
the use of the algorithm for tailoring risk assessment to the speciﬁc
circumstances of the patient and have important implications for
reducing unnecessary screening and saving costs.
http://dx.doi.org/10.1016/j.ijid.2014.03.1305
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Pneumococcal conjugate vaccine (non-typeable
Haemophilus inﬂuenzae (NTHi) Protein D,
diphtheria or tetanus toxoid conjugates) in
prevention of acute otitis media in children: A
cohort study
T.G.T. Chu ∗, D.R.I.R. Cachola
University of Santo Tomas Hospital, Manila,
Philippines
Background: Acute otitis media (AOM) is a common diagnosis
among children. The most common causative bacteria in AOM are
Streptococcus pneumoniae, Haemophilus inﬂuenzae, and Moraxella
catarrhalis. In March 2009, a pneumococcal vaccine containing
ten serotype-speciﬁc polysaccharides conjugated to Haemophilus
inﬂuenzae protein D, tetanus toxoid, and diphtheria toxoid as the
carrier proteins was developed and licensed.
Methods & Materials: Objectives: To compare the incidence of
AOMamong the children ages 2months to 6months old previously
given 3 doses of Pneumococcal conjugate vaccine (PCV) and those
who did not received the vaccine over a period of one year.
Study Design: Historical Cohort Study
Setting: Earnshaw Health Center, Sampaloc, Manila
Participant: A total of 176 subjects participated in the
study.Exposed Group: children vaccinated with 3 doses of PCV.
Unexposed Group: children not vaccinated with PCV.
Methodology: Medical records of both exposed and unexposed
groups were reviewed. Both groups underwent history and physi-
cal examination including otoscopy and any sign and symptoms of
active ear infection were noted.
Results: The overall incidence of AOM was 5.11% (9 out of 176).
An incidence of 3.75% (8 out of 80) and 6.25% (6 out of 96) had
AOM among the exposed and unexposed groups, respectively. A
Chi-square test value of 0.165 (p value =0.685) was obtained. The
relative risk (RR) was computed at 0.6 (95 percent CI 0.155, 2.323).
The number needed to treat (NNT) is 40.
Conclusion: The result showed no difference in the develop-
ment of AOM in the two groups, however, PCV based on the relative
risk is still beneﬁcial in preventing AOM in children.
http://dx.doi.org/10.1016/j.ijid.2014.03.1306
